Piper Sandler reaffirmed its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a steady price target of $32.00. The firm's analysis was based on a recent survey of ophthalmologists ...

Even when we think we are holding our gaze perfectly still, our eyes make tiny, involuntary movements. While these ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

In this CE activity, experts in the field will assess how advances in imaging and new therapies for the management of geographic atrophy secondary ... and management of retinal vein occlusion.

The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer ... for the management of geographic atrophy secondary to age-related macular ...

AI Optics is also collaborating with NYU Langone Health with the goal of advancing the accessibility and implementation of retinal screening technology. According to the company, this clearance “marks ...

Securities reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a stable price target of $30.00, following the company's announcement of its first ex-US approval for Syfovre in ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ... 1 "The approval of SYFOVRE marks a significant milestone for GA patients ...

"The approval of SYFOVRE marks a significant milestone for GA patients ... caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by ...

for adult patients suffering from geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This marks the first approved treatment for GA in Australia, offering hope to over ...

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the every-other-month ...